Fig. 6.

ADCC assay using NK cells from a cancer patient with NSCLC against autologous PBMC sorted to enrich for PD-L1, or H460 or H441 human lung tumor cells. a PD-L1 expression in total PBMC, and PBMC magnetically sorted via negative and positive selection to enrich for PD-L1 negative and PD-L1 positive fractions, respectively. b PD-L1 expression in H460 and H441 cells. c NK cells were purified from PBMC from a cancer patient using negative magnetic selection. In vitro ADCC assays were performed at effector:target ratio of 25:1, using an IgG1 isotype control antibody (gray bars, 1 ng/mL) or avelumab (black bars, 1 ng/mL). Results are displayed as mean + SEM of triplicate wells. Data analyzed with unpaired T-test comparing avelumab vs isotype control; **p < 0.01, ***p < 0.001; ns: not significant. d Comparison of PD-L1 expression (% positivity and mean fluorescence intensity, MFI) in the PD-L1⁺ enriched PBMC fraction from three cancer patients compared to H460 and H441 cells